Veracyte (VCYT) announced it has met its targeted enrollment for the NIGHTINGALE trial, which aims to evaluate the clinical utility of its Percepta Nasal Swab test.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
- Veracyte management to meet with Craig-Hallum
- Cautious Outlook on Veracyte: Sell Rating Amid Market Uncertainties and Valuation Concerns
- Veracyte price target lowered to $28 from $29 at Morgan Stanley
- Veracyte’s Strong Clinical Evidence and Market Growth Justify Buy Rating
- Veracyte Inc’s Earnings Call Highlights Robust Growth and Strategic Milestones